Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials

Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials

Background The sodium glucose cotransporter‐2 inhibitors are guideline‐recommended to treat heart failure across the spectrum of left ventricular ejection fraction; however, economic evaluations of adding sodium glucose cotransporter‐2 inhibitors to standard of care in chronic heart failure across a...

Full description

Bibliographic Details
Main Authors: Ankeet S. Bhatt, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Inder S. Anand, Akshay S. Desai, James C. Fang, Adrian F. Hernandez, Pardeep S. Jhund, Mikhail N. Kosiborod, Marc S. Sabatine, Sanjiv J. Shah, Orly Vardeny, John J. V. McMurray, Scott D. Solomon, Thomas A. Gaziano
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
cost effectiveness
heart failure
SGLT2 inhibitors
value
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.032279

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.032279

Similar Items